Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > LATEST
LATEST
-
COMMENTARY Comentary
March 26, 2007
-
ARCHIVE Required Nos. of Japanese Subjects Are Not Exorbitant: Mr Mori from PMDA
March 26, 2007
-
ARCHIVE Philips Simplicity Event in Hong Kong Highlights Philips' "Sense and Simplicity" in Healthcare
March 26, 2007
-
ARCHIVE REGULATORY NEWS IN BRIEF
March 26, 2007
-
ARCHIVE Takeda Acquires Paradigm of the UK
March 26, 2007
-
ARCHIVE Operating Profit Rate for 28 FJPWA-Affiliated OTC Drug Wholesalers Up 0.41 Points
March 26, 2007
-
ARCHIVE Nippon Chemiphar to Enter Chinese Market, Expand Generic Business
March 26, 2007
-
ARCHIVE Spread of Use of Steroids Reduces Asthma Deaths: GSK Seminar
March 26, 2007
-
ARCHIVE SymBio Licenses AB-1001 from Abeille
March 26, 2007
-
ARCHIVE Multiple Drug-Resistant P. Aeruginosa Detected in 85.8% of Core Hospitals
March 26, 2007
-
ARCHIVE Wholesalers Should Ally with Dispensing Pharmacies: Mr Kimura
March 26, 2007
-
ARCHIVE Number of Local Gov't Hospitals Drops below 1,000: MIC White Paper
March 26, 2007
-
ARCHIVE BUSINESS NEWS IN BRIEF
March 26, 2007
-
COMMENTARY Japanese Pharma Companies' Licensing Policy: 1 (1) Takeda Pharmaceutical Co., Ltd.
March 26, 2007
-
ARCHIVE Generics to Be Listed for 6 Major Products with Sales of Over \10 Bil.
March 26, 2007
-
ARCHIVE 152 Generics Approved for the Same Indications as Original Drugs
March 26, 2007
-
ARCHIVE Generics Should Use the Same Excipients as Original Drugs: Dr Kawashima of Santen
March 26, 2007
-
ARCHIVE NEW PRODUCT
March 26, 2007
-
ARCHIVE Kyorin to License at Least 1 Compound Per Year at Late Stage
March 26, 2007
-
ARCHIVE Korosho Proposes 7 Measures to Promote Innovation
March 26, 2007
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…